[{"quiz_id": "20251216T183904770Z_deepseek-v3.2_seed131", "question_id": "20251216T183904770Z_deepseek-v3.2_seed131-001", "question": "A 58-year-old man with metastatic castration-resistant prostate cancer (mCRPC) on enzalutamide develops progressive disease with new liver metastases. He is switched to docetaxel plus prednisone. After 6 cycles, his PSA declines by 80% and liver lesions shrink, but he develops new-onset bilateral gynecomastia, mild hyperpigmentation of palmar creases, and worsening fatigue. Serum studies show: testosterone 12 ng/dL (low), LH 0.1 mIU/mL (low), FSH 0.2 mIU/mL (low), cortisol 4 mcg/dL (8 AM, low), ACTH 15 pg/mL (inappropriately normal), TSH 0.8 mIU/L, free T4 1.0 ng/dL. What is the most likely underlying mechanism for his new symptoms?", "options": ["Secondary adrenal insufficiency due to docetaxel-induced autoimmune hypophysitis", "Ectopic ACTH secretion from prostate cancer cells transforming to small cell neuroendocrine carcinoma", "Inhibition of CYP17A1 by residual enzalutamide leading to combined glucocorticoid and mineralocorticoid deficiency", "Docetaxel-induced primary testicular failure with subsequent feedback suppression of gonadotropins", "Paraneoplastic production of beta-hCG by treatment-emergent neuroendocrine-differentiated prostate cancer"], "answer": "C", "answer_index": 2, "explanation": "The clinical picture suggests combined glucocorticoid and androgen deficiency with low ACTH, consistent with secondary adrenal insufficiency due to central suppression. Enzalutamide is a potent androgen receptor inhibitor but also inhibits multiple CYP enzymes, including CYP17A1, which is required for glucocorticoid and androgen synthesis. When docetaxel suppresses tumor burden, residual enzalutamide (with a long half-life) continues to block adrenal steroidogenesis, causing a late-presenting adrenal crisis. Ectopic ACTH would elevate ACTH; autoimmune hypophysitis typically elevates TSH and causes other pituitary deficiencies; primary testicular failure elevates LH/FSH; beta-hCG causes gynecomastia but not adrenal insufficiency.", "generator_model": "deepseek-v3.2", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Medical Oncology", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: N (No defensible answer)\\nVerdict on keyed answer: Not defensible as best; keyed mechanism is medically incorrect.\\nKey stem clues: mCRPC on enzalutamide (a pure AR antagonist, not a CYP17A1 inhibitor) switched to docetaxel + prednisone; excellent tumor response; new gynecomastia, hyperpigmented palmar creases, fatigue; labs show very low testosterone with suppressed LH/FSH (central hypogonadism) and low morning cortisol with inappropriately normal ACTH (central/secondary adrenal insufficiency); thyroid axis preserved.\\nMain logical/medical issues: Option C attributes the picture to inhibition of CYP17A1 by enzalutamide causing combined glucocorticoid and mineralocorticoid deficiency. Enzalutamide does not clinically inhibit CYP17A1 or cause adrenal insufficiency; CYP17A1 blockade (e.g., abiraterone) primarily reduces glucocorticoids and androgens, often leading to mineralocorticoid excess, not deficiency. None of the other options fits the pattern of central adrenal insufficiency with central hypogonadism and normal TSH; however, the question offers no accurate mechanism among the choices, leaving no defensible best answer.\\nMinimal fix: Change the mechanism to abiraterone (a CYP17A1 inhibitor) with steroid taper/withdrawal and adjust the labs/wording accordingly, or replace option C with a mechanism consistent with enzalutamide’s known effects (pure AR blockade without adrenal suppression).\",\"medical_accuracy_score\":\"2\",\"logical_validity\":false,\"logical_false_reason\":\"N\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: N (No defensible answer)\nVerdict on keyed answer: Not defensible as best; keyed mechanism is medically incorrect.\nKey stem clues: mCRPC on enzalutamide (a pure AR antagonist, not a CYP17A1 inhibitor) switched to docetaxel + prednisone; excellent tumor response; new gynecomastia, hyperpigmented palmar creases, fatigue; labs show very low testosterone with suppressed LH/FSH (central hypogonadism) and low morning cortisol with inappropriately normal ACTH (central/secondary adrenal insufficiency); thyroid axis preserved.\nMain logical/medical issues: Option C attributes the picture to inhibition of CYP17A1 by enzalutamide causing combined glucocorticoid and mineralocorticoid deficiency. Enzalutamide does not clinically inhibit CYP17A1 or cause adrenal insufficiency; CYP17A1 blockade (e.g., abiraterone) primarily reduces glucocorticoids and androgens, often leading to mineralocorticoid excess, not deficiency. None of the other options fits the pattern of central adrenal insufficiency with central hypogonadism and normal TSH; however, the question offers no accurate mechanism among the choices, leaving no defensible best answer.\nMinimal fix: Change the mechanism to abiraterone (a CYP17A1 inhibitor) with steroid taper/withdrawal and adjust the labs/wording accordingly, or replace option C with a mechanism consistent with enzalutamide’s known effects (pure AR blockade without adrenal suppression).", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "N", "verdict": "FAIL", "fail_reason": "N"}, "judge_verdict": "FAIL", "judge_fail_reason": "N", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251216T183904770Z_deepseek-v3.2_seed131", "question_id": "20251216T183904770Z_deepseek-v3.2_seed131-002", "question": "A 32-year-old woman with common variable immunodeficiency (CVID) on monthly IVIG develops acute severe headache, photophobia, and neck stiffness 36 hours after her infusion. LP shows: opening pressure 28 cm H2O, WBC 2/μL, protein 40 mg/dL, glucose 60 mg/dL (serum 95 mg/dL). Gram stain and culture negative. MRI brain with contrast is normal. She has had two similar but milder episodes in the past 12 months, always within 48 hours of IVIG. Which intervention is most likely to prevent recurrence while maintaining adequate immune protection?", "options": ["Switch to subcutaneous immunoglobulin (SCIG) at the same monthly dose", "Pre‑infusion high‑dose corticosteroid (e.g., methylprednisolone 1 g IV)", "Change IVIG product to a sucrose‑free, low‑osmolality formulation", "Administer IVIG at a slower infusion rate (e.g., over 72 hours) with pre‑hydration", "Replace IVIG with prophylactic antibiotics and as‑needed plasma infusions"], "answer": "A", "answer_index": 0, "explanation": "This describes aseptic meningitis secondary to IVIG, a well‑known complication related to high peak IgG levels and cytokine release. Switching to SCIG provides steady‑state IgG levels without peaks, dramatically reducing meningitis risk while maintaining protection. Slower infusion or changing formulation may reduce but not eliminate risk in susceptible patients. Pre‑infusion steroids are not routinely effective and pose long‑term risks. Discontinuing immunoglobulin replacement in CVID would lead to serious infections despite antibiotics.", "generator_model": "deepseek-v3.2", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Allergy / Immunology", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: CVID on monthly IVIG; onset of severe headache, photophobia, neck stiffness 36 hours post‑infusion; CSF essentially normal except mildly elevated opening pressure and very low WBC with normal protein and near‑normal CSF:serum glucose; negative Gram stain/culture; normal MRI; recurrent similar episodes temporally linked to IVIG. Together, this is classic IVIG‑associated aseptic meningitis, mediated by high transient serum IgG peaks.\\nOption A (switch to SCIG) is best because SCIG produces steadier IgG levels with minimal peaks and is specifically recommended in patients with recurrent systemic adverse reactions (including aseptic meningitis) while preserving immunoprotection.\\nB: Very high‑dose steroids (1 g) are disproportionate, risky chronically, and not reliably preventive; not standard for this setting. C: Changing to sucrose‑free, low‑osmolality IVIG mainly addresses renal risk; aseptic meningitis can occur with multiple products, so this may not reliably prevent recurrence. D: Slower rate and hydration may reduce reactions but are less effective than changing to SCIG and do not eliminate peak‑level issue. E: Stopping Ig replacement in CVID is contraindicated; prophylactic antibiotics are inadequate.\\nMinimal fix: Clarify in stem that she is otherwise doing well on IVIG (no efficacy concerns) and that meningitis occurs despite standard rate adjustments to further justify SCIG switch.\\n\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: CVID on monthly IVIG; onset of severe headache, photophobia, neck stiffness 36 hours post‑infusion; CSF essentially normal except mildly elevated opening pressure and very low WBC with normal protein and near‑normal CSF:serum glucose; negative Gram stain/culture; normal MRI; recurrent similar episodes temporally linked to IVIG. Together, this is classic IVIG‑associated aseptic meningitis, mediated by high transient serum IgG peaks.\nOption A (switch to SCIG) is best because SCIG produces steadier IgG levels with minimal peaks and is specifically recommended in patients with recurrent systemic adverse reactions (including aseptic meningitis) while preserving immunoprotection.\nB: Very high‑dose steroids (1 g) are disproportionate, risky chronically, and not reliably preventive; not standard for this setting. C: Changing to sucrose‑free, low‑osmolality IVIG mainly addresses renal risk; aseptic meningitis can occur with multiple products, so this may not reliably prevent recurrence. D: Slower rate and hydration may reduce reactions but are less effective than changing to SCIG and do not eliminate peak‑level issue. E: Stopping Ig replacement in CVID is contraindicated; prophylactic antibiotics are inadequate.\nMinimal fix: Clarify in stem that she is otherwise doing well on IVIG (no efficacy concerns) and that meningitis occurs despite standard rate adjustments to further justify SCIG switch.\n", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251216T183904770Z_deepseek-v3.2_seed131", "question_id": "20251216T183904770Z_deepseek-v3.2_seed131-003", "question": "An 87‑year‑old man with moderate Alzheimer dementia (MoCA 14/30), hypertension, and chronic kidney disease (eGFR 28 mL/min/1.73m²) is admitted from assisted living for acute confusion and agitation. He has been on donepezil 10 mg daily for 3 years. In the ED, he receives lorazepam 1 mg IM for severe agitation, with minimal effect. Inpatient medications include amlodipine, losartan, and aspirin. Over 48 hours, he develops persistent non‑rhythmic myoclonic jerks of the face and limbs, fluctuating alertness, and autonomic instability (HR 110-140, BP 170/95). EEG shows generalized periodic discharges with triphasic morphology. MRI brain is unchanged from baseline (moderate atrophy). What is the most likely diagnosis?", "options": ["Creutzfeldt‑Jakob disease", "Serotonin syndrome from an undetected SSRI", "Donepezil toxicity in the setting of acute kidney injury", "Nonconvulsive status epilepticus due to underlying neurodegeneration", "Acute anticholinergic delirium from a newly started medication"], "answer": "C", "answer_index": 2, "explanation": "The presentation with myoclonus, autonomic instability, altered mental status, and triphasic waves on EEG in a patient on donepezil with advanced CKD suggests donepezil toxicity. Donepezil is renally excreted, and acute kidney injury (even mild) can precipitate toxicity. Triphasic waves are classically associated with metabolic/toxic encephalopathies, including acetylcholinesterase inhibitor toxicity. Creutzfeldt‑Jakob disease would show rapid progression and MRI diffusion abnormalities. Serotonin syndrome requires a serotonergic agent. Nonconvulsive status typically shows rhythmic epileptiform discharges. Anticholinergic delirium causes dry skin, not myoclonus or triphasic waves.", "generator_model": "deepseek-v3.2", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Geriatrics", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: N. Verdict on keyed answer: No clearly defensible best answer. Key stem clues: 87-year-old with moderate Alzheimer dementia, CKD (eGFR 28) but no documented acute kidney injury or change in creatinine; long-term stable donepezil use; acute onset confusion/agitation, treated with a single lorazepam dose; evolving fluctuating encephalopathy, nonrhythmic myoclonus, autonomic instability, EEG with generalized periodic triphasic discharges, MRI unchanged from prior. The keyed answer (donepezil toxicity) is poorly supported: in clinical pharmacology, donepezil is not primarily renally cleared and standard references state no dose adjustment is required in renal impairment; linking triphasic waves specifically to acetylcholinesterase inhibitor toxicity is not standard teaching. Other options are also problematic: CJD is unlikely with unchanged MRI and an acute presentation but triphasic GPDs and myoclonus are compatible; nonconvulsive status epilepticus could present with altered mental status and periodic discharges, but the described EEG is more typical of metabolic encephalopathy than NCSE; serotonin syndrome and anticholinergic delirium require offending agents not provided. Because the question omits critical data (current kidney function, other toxins, metabolic labs) and is anchored on a non-consensus pharmacologic claim, no option is clearly defensible. Minimal fix: either rekey to an etiology clearly supported by accurate pathophysiology and add confirmatory findings, or rewrite the stem to document acute renal failure and cite a truly renally cleared drug (e.g., memantine) instead of donepezil.\",\"medical_accuracy_score\":\"2\",\"logical_validity\":false,\"logical_false_reason\":\"N\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: N. Verdict on keyed answer: No clearly defensible best answer. Key stem clues: 87-year-old with moderate Alzheimer dementia, CKD (eGFR 28) but no documented acute kidney injury or change in creatinine; long-term stable donepezil use; acute onset confusion/agitation, treated with a single lorazepam dose; evolving fluctuating encephalopathy, nonrhythmic myoclonus, autonomic instability, EEG with generalized periodic triphasic discharges, MRI unchanged from prior. The keyed answer (donepezil toxicity) is poorly supported: in clinical pharmacology, donepezil is not primarily renally cleared and standard references state no dose adjustment is required in renal impairment; linking triphasic waves specifically to acetylcholinesterase inhibitor toxicity is not standard teaching. Other options are also problematic: CJD is unlikely with unchanged MRI and an acute presentation but triphasic GPDs and myoclonus are compatible; nonconvulsive status epilepticus could present with altered mental status and periodic discharges, but the described EEG is more typical of metabolic encephalopathy than NCSE; serotonin syndrome and anticholinergic delirium require offending agents not provided. Because the question omits critical data (current kidney function, other toxins, metabolic labs) and is anchored on a non-consensus pharmacologic claim, no option is clearly defensible. Minimal fix: either rekey to an etiology clearly supported by accurate pathophysiology and add confirmatory findings, or rewrite the stem to document acute renal failure and cite a truly renally cleared drug (e.g., memantine) instead of donepezil.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "N", "verdict": "FAIL", "fail_reason": "N"}, "judge_verdict": "FAIL", "judge_fail_reason": "N", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251216T183904770Z_deepseek-v3.2_seed131", "question_id": "20251216T183904770Z_deepseek-v3.2_seed131-004", "question": "A 45‑year‑old woman with metastatic HER2‑positive breast cancer (bone, liver) on first‑line therapy with trastuzumab, pertuzumab, and docetaxel achieves a partial response after 6 cycles. Maintenance trastuzumab/pertuzumab is continued. One year later, surveillance CT shows a new 2 cm pancreatic tail mass, biopsy‑proven adenocarcinoma consistent with breast primary (ER‑/PR‑/HER2 3+ by IHC). Next‑generation sequencing of the pancreatic lesion reveals an activating mutation in PIK3CA (H1047R) and no HER2 amplification by NGS (though IHC remains 3+). She has never received a CDK4/6 inhibitor or everolimus. What is the most appropriate next systemic therapy?", "options": ["Continue trastuzumab/pertuzumab and add capecitabine", "Switch to trastuzumab deruxtecan (T‑DXd)", "Switch to lapatinib plus capecitabine", "Switch to everolimus plus exemestane", "Switch to alpelisib plus fulvestrant"], "answer": "B", "answer_index": 1, "explanation": "This represents HER2‑positive breast cancer with apparent HER2 discordance (IHC 3+ but no amplification by NGS) and acquired PIK3CA mutation. Trastuzumab deruxtecan (T‑DXd) is effective even in HER2‑low disease and has shown activity in HER2‑positive cancers resistant to trastuzumab/pertuzumab. Continuing dual HER2 blockade with chemotherapy is less likely to work given possible HER2‑negative clone emergence. Lapatinib/capecitabine is an older second‑line option but inferior to T‑DXd. Everolimus/exemestane or alpelisib/fulvestrant target hormone pathway/PIK3CA but are for HR‑positive disease; here the tumor is ER‑/PR‑.", "generator_model": "deepseek-v3.2", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Medical Oncology", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\n\\nKey stem clues: Metastatic HER2‑positive breast cancer, first‑line trastuzumab/pertuzumab/docetaxel with response; progression about 1 year later with new metastatic lesion; biopsy confirms same HER2‑positive breast primary (ER‑/PR‑/HER2 3+), now with PIK3CA mutation; patient is currently on maintenance trastuzumab/pertuzumab. Question asks for the most appropriate next systemic therapy at first progression on trastuzumab/pertuzumab in an ER‑negative, HER2‑positive metastatic setting.\\n\\nCurrent standard of care per DESTINY‑Breast03 and guidelines is to switch to trastuzumab deruxtecan as preferred second‑line therapy after trastuzumab/pertuzumab‑based first line. This directly supports choice B. HER2 IHC 3+ status remains, making her eligible; lack of HER2 amplification on NGS does not override IHC for HER2‑targeted therapy selection.\\n\\nChoice A (continue HP + capecitabine) is nonstandard after clear progression. C (lapatinib/capecitabine) is now inferior to T‑DXd. D and E are for HR‑positive disease, whereas this tumor is ER‑/PR‑negative.\\n\\nMain medical issues: Minor nuance about HER2 discordance interpretation, but not misleading. \\n\\nMinimal fix: Explicitly state that progression is confirmed and HP should be discontinued to avoid any ambiguity about adding vs switching therapy.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\n\nKey stem clues: Metastatic HER2‑positive breast cancer, first‑line trastuzumab/pertuzumab/docetaxel with response; progression about 1 year later with new metastatic lesion; biopsy confirms same HER2‑positive breast primary (ER‑/PR‑/HER2 3+), now with PIK3CA mutation; patient is currently on maintenance trastuzumab/pertuzumab. Question asks for the most appropriate next systemic therapy at first progression on trastuzumab/pertuzumab in an ER‑negative, HER2‑positive metastatic setting.\n\nCurrent standard of care per DESTINY‑Breast03 and guidelines is to switch to trastuzumab deruxtecan as preferred second‑line therapy after trastuzumab/pertuzumab‑based first line. This directly supports choice B. HER2 IHC 3+ status remains, making her eligible; lack of HER2 amplification on NGS does not override IHC for HER2‑targeted therapy selection.\n\nChoice A (continue HP + capecitabine) is nonstandard after clear progression. C (lapatinib/capecitabine) is now inferior to T‑DXd. D and E are for HR‑positive disease, whereas this tumor is ER‑/PR‑negative.\n\nMain medical issues: Minor nuance about HER2 discordance interpretation, but not misleading. \n\nMinimal fix: Explicitly state that progression is confirmed and HP should be discontinued to avoid any ambiguity about adding vs switching therapy.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251216T183904770Z_deepseek-v3.2_seed131", "question_id": "20251216T183904770Z_deepseek-v3.2_seed131-005", "question": "A 28‑year‑old woman with idiopathic anaphylaxis presents with recurrent episodes of urticaria, angioedema, wheezing, and hypotension occurring 2-3 times monthly despite high‑dose antihistamines and montelukast. She undergoes exhaustive evaluation: normal tryptase, negative specific IgE to foods/venoms/drugs, no mastocytosis on bone marrow biopsy, and no physical urticaria triggers. During a supervised oral challenge to placebo in clinic, she develops identical symptoms with hypotension. Serum collected during the event shows elevated prostaglandin D2 (PGD2) but normal histamine and tryptase. Which therapy is most likely to be effective in preventing future episodes?", "options": ["Omalizumab (anti‑IgE)", "Rituximab (anti‑CD20)", "Imatinib (tyrosine kinase inhibitor)", "Continuous intravenous epinephrine infusion", "NSAID (e.g., indomethacin) prior to suspected triggers"], "answer": "E", "answer_index": 4, "explanation": "Elevated PGD2 with normal histamine/tryptase during symptoms suggests a prostaglandin‑mediated disorder, possibly a mast cell activation syndrome variant or idiopathic flush‑related anaphylaxis. NSAIDs inhibit cyclooxygenase and reduce PGD2 production, which can prevent episodes in select patients with prostaglandin‑driven symptoms. Omalizumab targets IgE‑mediated pathways, not primarily prostaglandin‑mediated. Rituximab is for autoimmune conditions. Imatinib is for mastocytosis with KIT mutations. Continuous epinephrine is not a preventive therapy and carries high risk.", "generator_model": "deepseek-v3.2", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Allergy / Immunology", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Idiopathic anaphylaxis with negative IgE/allergy workup; normal tryptase and histamine during a reproduced event; elevated PGD2 during symptoms; episodes refractory to standard prophylaxis (high‑dose antihistamines, montelukast). These findings point to a prostaglandin‑driven mast‑cell–related process or related PGD2‑mediated vascular reaction rather than classic IgE‑mediated anaphylaxis. NSAIDs such as indomethacin inhibit cyclooxygenase and decrease PGD2 synthesis, and are a recognized approach in select PGD2‑mediated flushing/anaphylactoid syndromes, making option E the most appropriate preventive strategy among the choices.\\nOther options: Omalizumab (A) targets IgE and is not primarily directed at a prostaglandin pathway; rituximab (B) is for B‑cell–mediated autoimmune disease; imatinib (C) is used for KIT‑mutant mastocytosis, which is explicitly excluded; continuous IV epinephrine (D) is acute rescue, not chronic prophylaxis and is unsafe long‑term.\\nMain issues: “Idiopathic anaphylaxis” plus normal histamine/tryptase is somewhat atypical but still compatible with a PGD2‑predominant mast‑cell activation picture. Minimal fix: Clarify diagnosis as “suspected PGD2‑mediated mast cell activation syndrome” to better align terminology with the lab pattern.\\n\",\"medical_accuracy_score\":\"4\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Idiopathic anaphylaxis with negative IgE/allergy workup; normal tryptase and histamine during a reproduced event; elevated PGD2 during symptoms; episodes refractory to standard prophylaxis (high‑dose antihistamines, montelukast). These findings point to a prostaglandin‑driven mast‑cell–related process or related PGD2‑mediated vascular reaction rather than classic IgE‑mediated anaphylaxis. NSAIDs such as indomethacin inhibit cyclooxygenase and decrease PGD2 synthesis, and are a recognized approach in select PGD2‑mediated flushing/anaphylactoid syndromes, making option E the most appropriate preventive strategy among the choices.\nOther options: Omalizumab (A) targets IgE and is not primarily directed at a prostaglandin pathway; rituximab (B) is for B‑cell–mediated autoimmune disease; imatinib (C) is used for KIT‑mutant mastocytosis, which is explicitly excluded; continuous IV epinephrine (D) is acute rescue, not chronic prophylaxis and is unsafe long‑term.\nMain issues: “Idiopathic anaphylaxis” plus normal histamine/tryptase is somewhat atypical but still compatible with a PGD2‑predominant mast‑cell activation picture. Minimal fix: Clarify diagnosis as “suspected PGD2‑mediated mast cell activation syndrome” to better align terminology with the lab pattern.\n", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251216T183904770Z_deepseek-v3.2_seed131", "question_id": "20251216T183904770Z_deepseek-v3.2_seed131-006", "question": "An 82‑year‑old woman with aortic stenosis (mean gradient 38 mm Hg, AVA 0.9 cm²), COPD (FEV1 45%), and stage 3 CKD is admitted with syncope. She lives independently but reports declining energy over 6 months. She is evaluated by cardiology and deemed high risk for surgical AVR but a candidate for TAVR. During shared decision‑making, which factor, if present, would most strongly argue against proceeding with TAVR?", "options": ["Recent fall with subdural hematoma requiring reversal of apixaban 3 months ago", "Moderate‑severe mitral regurgitation due to annular dilation", "Life expectancy estimated at less than 12 months due to metastatic lung cancer diagnosed 2 months ago", "Frailty score consistent with slow gait and low grip strength but able to perform ADLs", "Asymptomatic 4 cm abdominal aortic aneurysm noted on pre‑TAVR CT"], "answer": "C", "answer_index": 2, "explanation": "TAVR is indicated to improve quality of life and survival in patients with severe symptomatic aortic stenosis whose life expectancy is >12 months. A life expectancy <12 months due to metastatic cancer makes the procedural risks and recovery burdens unjustifiable. Recent subdural hematoma is a relative contraindication but may be timed. Moderate‑severe MR often improves post‑TAVR. Frailty alone does not preclude TAVR if the patient can participate in rehabilitation. A 4 cm AAA is below threshold for repair and not a contraindication.", "generator_model": "deepseek-v3.2", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Geriatrics", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Elderly patient with severe symptomatic aortic stenosis, high surgical risk but TAVR candidate; question asks which factor, if present, would most strongly argue against proceeding with TAVR. Choice C specifies life expectancy <12 months due to metastatic lung cancer. Guidelines emphasize that TAVR (and other valve interventions) are not recommended when noncardiac comorbidities limit life expectancy to <1 year or when no meaningful improvement in quality of life is expected. This is clearly a stronger contraindication than the relative/mitigatable issues in the other options.\\nOther options: A (recent subdural hematoma) is a relative contraindication but could be deferred and reconsidered; B (moderate‑severe functional MR) often improves after TAVR and is not a primary exclusion; D (frailty but independent in ADLs) raises risk but is not absolute; E (4‑cm AAA) is below repair threshold and not a contraindication. Thus C is uniquely best.\\nMain medical accuracy issues: None; explanation is consistent with contemporary TAVR criteria. \\nMinimal fix: Clarify in the stem that cardiology has assessed that valve intervention would otherwise be expected to improve symptoms and survival absent competing noncardiac illness.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Elderly patient with severe symptomatic aortic stenosis, high surgical risk but TAVR candidate; question asks which factor, if present, would most strongly argue against proceeding with TAVR. Choice C specifies life expectancy <12 months due to metastatic lung cancer. Guidelines emphasize that TAVR (and other valve interventions) are not recommended when noncardiac comorbidities limit life expectancy to <1 year or when no meaningful improvement in quality of life is expected. This is clearly a stronger contraindication than the relative/mitigatable issues in the other options.\nOther options: A (recent subdural hematoma) is a relative contraindication but could be deferred and reconsidered; B (moderate‑severe functional MR) often improves after TAVR and is not a primary exclusion; D (frailty but independent in ADLs) raises risk but is not absolute; E (4‑cm AAA) is below repair threshold and not a contraindication. Thus C is uniquely best.\nMain medical accuracy issues: None; explanation is consistent with contemporary TAVR criteria. \nMinimal fix: Clarify in the stem that cardiology has assessed that valve intervention would otherwise be expected to improve symptoms and survival absent competing noncardiac illness.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}]